BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: ABT-737 re-sensitized the CML cell line K562 to imatinib-induced cell killing in cells with imatinib-resistance mediated by BIM knockdown or BCL-2 overexpression32.